{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:01:32Z","timestamp":1788454892639,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10928-025-09979-2","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T15:34:20Z","timestamp":1747409660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A comprehensive review of 20 years of progress in nonclinical QT evaluation and proarrhythmic assessment"],"prefix":"10.1007","volume":"52","author":[{"given":"Eric","family":"Delpy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"B\u00e9tat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Delaunois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Drieu la Rochelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"9979_CR1","unstructured":"ICH (2005) ICH E14: The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. CPMP\/ICH\/2\/04 http:\/\/www.emea.eu.int\/pdfs\/human\/ich\/000204en.pdf:Accessed 23 November 2023"},{"key":"9979_CR2","unstructured":"ICH (2005) ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. CPMP\/ICHhttp:\/\/www.emea.eu.int\/pdfs\/human\/ich\/042302en.pdf:Accessed 23 November 2023"},{"key":"9979_CR3","unstructured":"ICH (2000) ICH Topic S7A: Safety Pharmacology Studies for Human Pharmaceuticals. CPMP\/ICH\/539\/00 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-s-7-safety-pharmacology-studies-human-pharmaceuticals-step-5_en.pdf:Accessed 23 November 2023"},{"key":"9979_CR4","unstructured":"ICH (2022) ICH E14\/S7B Q&As. Clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential - Questions and answers. https:\/\/database.ich.org\/sites\/default\/files\/E14-S7B_QAs_Step4_2022_0221.pdf Accessed 4 January 2025"},{"issue":"2","key":"9979_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/clpt.2011.224","volume":"91","author":"JC Bouvy","year":"2012","unstructured":"Bouvy JC, Koopmanschap MA, Shah RR, Schellekens H (2012) The cost-effectiveness of drug regulation: the example of thorough QT\/QTc studies. Clin Pharmacol Ther 91(2):281\u2013288. https:\/\/doi.org\/10.1038\/clpt.2011.224","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"9979_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/cpt.2137","volume":"109","author":"DG Strauss","year":"2021","unstructured":"Strauss DG, Wu WW, Li Z, Koerner J, Garnett C (2021) Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B Updates). Clin Pharmacol Ther 109(2):319\u2013333. https:\/\/doi.org\/10.1002\/cpt.2137","journal-title":"Clin Pharmacol Ther"},{"key":"9979_CR7","doi-asserted-by":"publisher","first-page":"104662","DOI":"10.1016\/j.yrtph.2020.104662","volume":"114","author":"AM Avila","year":"2020","unstructured":"Avila AM, Bebenek I, Bonzo JA, Bourcier T, Davis Bruno KL, Carlson DB, Dubinion J, Elayan I, Harrouk W, Lee SL, Mendrick DL, Merrill JC, Peretz J, Place E, Saulnier M, Wange RL, Yao J, Zhao D, Brown PC (2020) An FDA\/CDER perspective on nonclinical testing strategies: classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol 114:104662. https:\/\/doi.org\/10.1016\/j.yrtph.2020.104662","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"9979_CR8","first-page":"263","volume":"59","author":"F Dessertenne","year":"1966","unstructured":"Dessertenne F (1966) [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss 59(2):263\u2013272","journal-title":"Arch Mal Coeur Vaiss"},{"issue":"10","key":"9979_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.121.055783","volume":"144","author":"S Viskin","year":"2021","unstructured":"Viskin S, Chorin E, Viskin D, Hochstadt A, Schwartz AL, Rosso R (2021) Polymorphic ventricular tachycardia: terminology, mechanism, diagnosis, and emergency therapy. Circulation 144(10):823\u2013839. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055783","journal-title":"Circulation"},{"issue":"1","key":"9979_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","volume":"187","author":"JP Valentin","year":"2022","unstructured":"Valentin JP, Hoffmann P, Ortemann-Renon C, Koerner J, Pierson J, Gintant G, Willard J, Garnett C, Skinner M, Vargas HM, Wisialowski T, Pugsley MK (2022) The challenges of predicting Drug-Induced QTc prolongation in humans. Toxicol Sci 187(1):3\u201324. https:\/\/doi.org\/10.1093\/toxsci\/kfac013","journal-title":"Toxicol Sci"},{"key":"9979_CR11","unstructured":"CPMP (1997) Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products. European Agency for the Evaluation of Medicinal Products. Accessed 14 January 2025"},{"key":"9979_CR12","doi-asserted-by":"publisher","unstructured":"Bialecki RA, Gallacher DJ, Valentin J-P (2024) Drug-Induced QT Prolongation. In: McQueen C (ed) Reference Module in Biomedical Sciences. Elsevier. https:\/\/doi.org\/10.1016\/B978-0-323-95488-4.00070-X","DOI":"10.1016\/B978-0-323-95488-4.00070-X"},{"issue":"1","key":"9979_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1476-5381.2009.00207.x","volume":"159","author":"CE Pollard","year":"2010","unstructured":"Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP (2010) An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159(1):12\u201321. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00207.x","journal-title":"Br J Pharmacol"},{"key":"9979_CR14","volume-title":"Last update December 18, 2024 Edn","author":"PharmaPendium","year":"2024","unstructured":"PharmaPendium (2024) Last update December 18, 2024 Edn. Elsevier, Amsterdam, Netherlands"},{"issue":"7","key":"9979_CR15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/j.1476-5381.1996.tb15295.x","volume":"117","author":"FL Puisieux","year":"1996","unstructured":"Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA (1996) Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit purkinje fibres. Br J Pharmacol 117(7):1377\u20131379. https:\/\/doi.org\/10.1111\/j.1476-5381.1996.tb15295.x","journal-title":"Br J Pharmacol"},{"issue":"3","key":"9979_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/sj.bjp.0706070","volume":"144","author":"P Champeroux","year":"2005","unstructured":"Champeroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY, Richard S (2005) Prediction of the risk of torsade de pointes using the model of isolated canine purkinje fibres. Br J Pharmacol 144(3):376\u2013385. https:\/\/doi.org\/10.1038\/sj.bjp.0706070","journal-title":"Br J Pharmacol"},{"issue":"1","key":"9979_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.vascn.2005.04.011","volume":"52","author":"CL Lawrence","year":"2005","unstructured":"Lawrence CL, Pollard CE, Hammond TG, Valentin JP (2005) Nonclinical proarrhythmia models: predicting Torsades de pointes. J Pharmacol Toxicol Methods 52(1):46\u201359. https:\/\/doi.org\/10.1016\/j.vascn.2005.04.011","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"7","key":"9979_CR18","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/bjp.2008.195","volume":"154","author":"CL Lawrence","year":"2008","unstructured":"Lawrence CL, Pollard CE, Hammond TG, Valentin JP (2008) In vitro models of proarrhythmia. Br J Pharmacol 154(7):1516\u20131522. https:\/\/doi.org\/10.1038\/bjp.2008.195","journal-title":"Br J Pharmacol"},{"issue":"1","key":"9979_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.vascn.2013.04.004","volume":"68","author":"KA Beattie","year":"2013","unstructured":"Beattie KA, Luscombe C, Williams G, Munoz-Muriedas J, Gavaghan DJ, Cui Y, Mirams GR (2013) Evaluation of an in Silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge. J Pharmacol Toxicol Methods 68(1):88\u201396. https:\/\/doi.org\/10.1016\/j.vascn.2013.04.004","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"1","key":"9979_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cvr\/cvr044","volume":"91","author":"GR Mirams","year":"2011","unstructured":"Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D (2011) Simulation of multiple ion channel block provides improved early prediction of compounds\u2019 clinical Torsadogenic risk. Cardiovasc Res 91(1):53\u201361. https:\/\/doi.org\/10.1093\/cvr\/cvr044","journal-title":"Cardiovasc Res"},{"issue":"3","key":"9979_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.vascn.2004.03.008","volume":"49","author":"JP Valentin","year":"2004","unstructured":"Valentin JP, Hoffmann P, De Clerck F, Hammond TG, Hondeghem L (2004) Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods 49(3):171\u2013181. https:\/\/doi.org\/10.1016\/j.vascn.2004.03.008","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"3","key":"9979_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/00005344-199809000-00013","volume":"32","author":"L Eckardt","year":"1998","unstructured":"Eckardt L, Haverkamp W, Mertens H, Johna R, Clague JR, Borggrefe M, Breithardt G (1998) Drug-related Torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin. J Cardiovasc Pharmacol 32(3):425\u2013434. https:\/\/doi.org\/10.1097\/00005344-199809000-00013","journal-title":"J Cardiovasc Pharmacol"},{"key":"9979_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jelectrocard.2004.08.007","volume":"37 Suppl","author":"N Stockbridge","year":"2004","unstructured":"Stockbridge N, Throckmorton DC (2004) Regulatory advice on evaluation of the proarrhythmic potential of drugs. J Electrocardiol 37 Suppl:40\u201341. https:\/\/doi.org\/10.1016\/j.jelectrocard.2004.08.007","journal-title":"J Electrocardiol"},{"key":"9979_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.vascn.2015.06.004","volume":"76","author":"I Cavero","year":"2015","unstructured":"Cavero I, Holzgrefe H (2015) CiPA: ongoing testing, future qualification procedures, and pending issues. J Pharmacol Toxicol Methods 76:27\u201337. https:\/\/doi.org\/10.1016\/j.vascn.2015.06.004","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"7","key":"9979_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd.2015.34","volume":"15","author":"G Gintant","year":"2016","unstructured":"Gintant G, Sager PT, Stockbridge N (2016) Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov 15(7):457\u2013471. https:\/\/doi.org\/10.1038\/nrd.2015.34","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"9979_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/clpt.2014.155","volume":"96","author":"L Johannesen","year":"2014","unstructured":"Johannesen L, Vicente J, Mason JW, Sanabria C, Waite-Labott K, Hong M, Guo P, Lin J, Sorensen JS, Galeotti L, Florian J, Ugander M, Stockbridge N, Strauss DG (2014) Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, Quinidine, Ranolazine, and verapamil. Clin Pharmacol Ther 96(5):549\u2013558. https:\/\/doi.org\/10.1038\/clpt.2014.155","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"9979_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861\u2013872. https:\/\/doi.org\/10.1016\/j.cell.2007.11.019","journal-title":"Cell"},{"key":"9979_CR28","doi-asserted-by":"publisher","unstructured":"Schmid C, Abi-Gerges N, Leitner MG, Zellner D, Rast G (2021) Ion channel expression and electrophysiology of singular human (Primary and induced pluripotent stem Cell-Derived). Cardiomyocytes Cells 10(12). https:\/\/doi.org\/10.3390\/cells10123370","DOI":"10.3390\/cells10123370"},{"issue":"4","key":"9979_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41573-022-00633-x","volume":"22","author":"F Pognan","year":"2023","unstructured":"Pognan F, Beilmann M, Boonen HCM, Czich A, Dear G, Hewitt P, Mow T, Oinonen T, Roth A, Steger-Hartmann T, Valentin JP, Van Goethem F, Weaver RJ, Newham P (2023) The evolving role of investigative toxicology in the pharmaceutical industry. Nat Rev Drug Discov 22(4):317\u2013335. https:\/\/doi.org\/10.1038\/s41573-022-00633-x","journal-title":"Nat Rev Drug Discov"},{"key":"9979_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.vascn.2016.06.007","volume":"81","author":"Y Kanda","year":"2016","unstructured":"Kanda Y, Yamazaki D, Kurokawa J, Inutsuka T, Sekino Y (2016) Points to consider for a validation study of iPS cell-derived cardiomyocytes using a multi-electrode array system. J Pharmacol Toxicol Methods 81:196\u2013200. https:\/\/doi.org\/10.1016\/j.vascn.2016.06.007","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"4","key":"9979_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jphs.2018.10.010","volume":"138","author":"Y Kanda","year":"2018","unstructured":"Kanda Y, Yamazaki D, Osada T, Yoshinaga T, Sawada K (2018) Development of Torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS cardiac safety assessment (JiCSA) update. J Pharmacol Sci 138(4):233\u2013239. https:\/\/doi.org\/10.1016\/j.jphs.2018.10.010","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"9979_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/cpt.2029","volume":"109","author":"HM Vargas","year":"2021","unstructured":"Vargas HM, Rolf MG, Wisialowski TA, Achanzar W, Bahinski A, Bass A, Benson CT, Chaudhary KW, Couvreur N, Dota C, Engwall MJ, Michael Foley C, Gallacher D, Greiter-Wilke A, Guillon JM, Guth B, Himmel HM, Hegele-Hartung C, Ito M, Jenkinson S, Chiba K, Lagrutta A, Levesque P, Martel E, Okai Y, Peri R, Pointon A, Qu Y, Teisman A, Traebert M, Yoshinaga T, Gintant GA, Leishman DJ, Valentin JP (2021) Time for a fully integrated Nonclinical-Clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective. Clin Pharmacol Ther 109(2):310\u2013318. https:\/\/doi.org\/10.1002\/cpt.2029","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9979_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s0008-6363(02)00846-5","volume":"58","author":"WS Redfern","year":"2003","unstructured":"Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58(1):32\u201345. https:\/\/doi.org\/10.1016\/s0008-6363(02)00846-5","journal-title":"Cardiovasc Res"},{"key":"9979_CR34","doi-asserted-by":"publisher","first-page":"106900","DOI":"10.1016\/j.vascn.2020.106900","volume":"105","author":"DJ Leishman","year":"2020","unstructured":"Leishman DJ, Abernathy MM, Wang EB (2020) Revisiting the hERG safety margin after 20 years of routine hERG screening. J Pharmacol Toxicol Methods 105:106900. https:\/\/doi.org\/10.1016\/j.vascn.2020.106900","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"11","key":"9979_CR35","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/jcph.2309","volume":"63","author":"B Darpo","year":"2023","unstructured":"Darpo B, Leishman DJ (2023) The new S7B\/E14 Q&A document provides additional opportunities to replace the thorough QT study. J Clin Pharmacol 63(11):1256\u20131274. https:\/\/doi.org\/10.1002\/jcph.2309","journal-title":"J Clin Pharmacol"},{"key":"9979_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-73317-9_147-1","volume-title":"Drug discovery and evaluation: safety and Pharmacokinetic assays","author":"J-P Valentin","year":"2024","unstructured":"Valentin J-P, Leishman D, Vargas HM (2024) Overview of the ICH E14\/S7B: questions and answers. In: Hock FJ, Pugsley MK (eds) Drug discovery and evaluation: safety and Pharmacokinetic assays, Third edn. Springer, Cham., pp 23\u201340. doi:https:\/\/doi.org\/10.1007\/978-3-030-73317-9_147-1","edition":"Third"},{"issue":"2","key":"9979_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.vascn.2008.11.001","volume":"59","author":"P Champeroux","year":"2009","unstructured":"Champeroux P, Martel E, Fowler JS, Maurin A, Sola ML, Jude S, Elamrani F, Weyn AA, Laveissiere A, Lala P, Richard S (2009) Calculation of QT shift in Non clinical safety Pharmacology studies. J Pharmacol Toxicol Methods 59(2):73\u201385. https:\/\/doi.org\/10.1016\/j.vascn.2008.11.001","journal-title":"J Pharmacol Toxicol Methods"},{"key":"9979_CR38","doi-asserted-by":"publisher","first-page":"107211","DOI":"10.1016\/j.vascn.2022.107211","volume":"117","author":"ND Ether","year":"2022","unstructured":"Ether ND, Leishman DJ, Bailie MB, Lauver DA (2022) QT ratio: A simple solution to individual QT correction. J Pharmacol Toxicol Methods 117:107211. https:\/\/doi.org\/10.1016\/j.vascn.2022.107211","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"2","key":"9979_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/toxsci\/kfy270","volume":"167","author":"RJ Weaver","year":"2019","unstructured":"Weaver RJ, Valentin JP (2019) Today\u2019s challenges to De-Risk and predict drug safety in human Mind-the-Gap. Toxicol Sci 167(2):307\u2013321. https:\/\/doi.org\/10.1093\/toxsci\/kfy270","journal-title":"Toxicol Sci"},{"issue":"3","key":"9979_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.vascn.2011.08.006","volume":"65","author":"DJ Leishman","year":"2012","unstructured":"Leishman DJ, Beck TW, Dybdal N, Gallacher DJ, Guth BD, Holbrook M, Roche B, Wallis RM (2012) Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the safety Pharmacology society. J Pharmacol Toxicol Methods 65(3):93\u2013101. https:\/\/doi.org\/10.1016\/j.vascn.2011.08.006","journal-title":"J Pharmacol Toxicol Methods"},{"key":"9979_CR41","volume-title":"The principles of humane experimental technique","author":"WMS Russell","year":"1959","unstructured":"Russell WMS, Burch RL (1959) The principles of humane experimental technique. Methuen & co Ltd, London"},{"key":"9979_CR42","unstructured":"European Commission (DG for Internal Markets I, Entrepreneurship and SMEs) (2023) Communication from the Commission on the European Citizens\u2019 Initiative (ECI) \u2018Save cruelty-free cosmetics \u2013 Commit to a Europe without animal testing\u2019. Brussels"},{"issue":"4","key":"9979_CR43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cpt.60","volume":"97","author":"B Darpo","year":"2015","unstructured":"Darpo B, Benson C, Dota C, Ferber G, Garnett C, Green CL, Jarugula V, Johannesen L, Keirns J, Krudys K, Liu J, Ortemann-Renon C, Riley S, Sarapa N, Smith B, Stoltz RR, Zhou M, Stockbridge N (2015) Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther 97(4):326\u2013335. https:\/\/doi.org\/10.1002\/cpt.60","journal-title":"Clin Pharmacol Ther"},{"key":"9979_CR44","doi-asserted-by":"publisher","unstructured":"Komatsu R, Mizuno H, Ishizaka T, Ito A, Jikuzono T, Kakoi T, Bando M, Koga T, Handa J, Takahashi Y, Kanno A, Ozaki H, Chiba K Japan activity for improvement of cardiovascular evaluation by telemetry s (2019) Exposure-response analysis of drug-induced QT interval prolongation in telemetered monkeys for translational prediction to human. J Pharmacol Toxicol Methods 99:106606. https:\/\/doi.org\/10.1016\/j.vascn.2019.106606","DOI":"10.1016\/j.vascn.2019.106606"},{"issue":"3","key":"9979_CR45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/cts.13454","volume":"16","author":"MJ Engwall","year":"2023","unstructured":"Engwall MJ, Baublits J, Chandra FA, Jones ZW, Wahlstrom J, Chui RW, Vargas HM (2023) Evaluation of Levocetirizine in beagle dog and cynomolgus monkey telemetry assays: defining the no QTc effect profile by timepoint and concentration-QTc analysis. Clin Transl Sci 16(3):436\u2013446. https:\/\/doi.org\/10.1111\/cts.13454","journal-title":"Clin Transl Sci"},{"key":"9979_CR46","doi-asserted-by":"publisher","first-page":"107067","DOI":"10.1016\/j.vascn.2021.107067","volume":"109","author":"J Baublits","year":"2021","unstructured":"Baublits J, Vargas HM, Engwall MJ (2021) The in vivo QTc core assay: an evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies. J Pharmacol Toxicol Methods 109:107067. https:\/\/doi.org\/10.1016\/j.vascn.2021.107067","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"9979_CR47","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1111\/cts.13103","volume":"14","author":"RW Chui","year":"2021","unstructured":"Chui RW, Baublits J, Chandra FA, Jones ZW, Engwall MJ, Vargas HM (2021) Evaluation of Moxifloxacin in canine and non-human primate telemetry assays: comparison of QTc interval prolongation by timepoint and concentration-QTc analysis. Clin Transl Sci 14(6):2379\u20132390. https:\/\/doi.org\/10.1111\/cts.13103","journal-title":"Clin Transl Sci"},{"key":"9979_CR48","doi-asserted-by":"publisher","unstructured":"Leishman DJ, Holdsworth DL, Best DD, Roche BM (2023) Comparing the sensitivity of cross-over and parallel study designs for QTc assessment: an analysis based on a single large study of Moxifloxacin in 48 nonhuman primates. J Pharmacol Toxicol Methods 107299. https:\/\/doi.org\/10.1016\/j.vascn.2023.107299","DOI":"10.1016\/j.vascn.2023.107299"},{"issue":"1","key":"9979_CR49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/cpt.3283","volume":"116","author":"AM Betat","year":"2024","unstructured":"Betat AM, Delaunois A, Delpy E, Loiseau M, Maurin A, Poizat G, Posseme C, Weinelt F, Drieu la Rochelle C, Martel E, Valentin JP (2024) Results from a joined prospective study to evaluate the sensitivity of the in vivo dog QT assay in line with the ICH E14\/S7B Q&A best practices. Clin Pharmacol Ther 116(1):106\u2013116. https:\/\/doi.org\/10.1002\/cpt.3283","journal-title":"Clin Pharmacol Ther"},{"key":"9979_CR50","doi-asserted-by":"publisher","first-page":"107270","DOI":"10.1016\/j.vascn.2023.107270","volume":"123","author":"EI Rossman","year":"2023","unstructured":"Rossman EI, Wisialowski TA, Vargas HM, Valentin JP, Rolf MG, Roche BM, Riley S, Pugsley MK, Nichols J, Li D, Leishman DJ, Kleiman RB, Greiter-Wilke A, Gintant GA, Engwall MJ, Delaunois A, Authier S (2023) Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: delivering high quality QTc data to support ICH E14\/S7B Q&As. J Pharmacol Toxicol Methods 123:107270. https:\/\/doi.org\/10.1016\/j.vascn.2023.107270","journal-title":"J Pharmacol Toxicol Methods"},{"key":"9979_CR51","doi-asserted-by":"publisher","first-page":"107265","DOI":"10.1016\/j.vascn.2023.107265","volume":"121","author":"HM Vargas","year":"2023","unstructured":"Vargas HM, Rossman EI, Wisialowski TA, Nichols J, Pugsley MK, Roche B, Gintant GA, Greiter-Wilke A, Kleiman RB, Valentin JP, Leishman DJ (2023) Improving the in vivo QTc assay: the value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute. J Pharmacol Toxicol Methods 121:107265. https:\/\/doi.org\/10.1016\/j.vascn.2023.107265","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"1","key":"9979_CR52","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/cpt.1647","volume":"107","author":"Z Li","year":"2020","unstructured":"Li Z, Mirams GR, Yoshinaga T, Ridder BJ, Han X, Chen JE, Stockbridge NL, Wisialowski TA, Damiano B, Severi S, Morissette P, Kowey PR, Holbrook M, Smith G, Rasmusson RL, Liu M, Song Z, Qu Z, Leishman DJ, Steidl-Nichols J, Rodriguez B, Bueno-Orovio A, Zhou X, Passini E, Edwards AG, Morotti S, Ni H, Grandi E, Clancy CE, Vandenberg J, Hill A, Nakamura M, Singer T, Polonchuk L, Greiter-Wilke A, Wang K, Nave S, Fullerton A, Sobie EA, Paci M, Musuamba Tshinanu F, Strauss DG (2020) General principles for the validation of proarrhythmia risk prediction models: an extension of the CiPA in Silico strategy. Clin Pharmacol Ther 107(1):102\u2013111. https:\/\/doi.org\/10.1002\/cpt.1647","journal-title":"Clin Pharmacol Ther"},{"key":"9979_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.vascn.2016.12.003","volume":"84","author":"H Ando","year":"2017","unstructured":"Ando H, Yoshinaga T, Yamamoto W, Asakura K, Uda T, Taniguchi T, Ojima A, Shinkyo R, Kikuchi K, Osada T, Hayashi S, Kasai C, Miyamoto N, Tashibu H, Yamazaki D, Sugiyama A, Kanda Y, Sawada K, Sekino Y (2017) A new paradigm for drug-induced Torsadogenic risk assessment using human iPS cell-derived cardiomyocytes. J Pharmacol Toxicol Methods 84:111\u2013127. https:\/\/doi.org\/10.1016\/j.vascn.2016.12.003","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"3","key":"9979_CR54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1021\/acsmedchemlett.9b00582","volume":"11","author":"MJ Blanco","year":"2020","unstructured":"Blanco MJ, Gardinier KM (2020) New chemical modalities and strategic thinking in early drug discovery. ACS Med Chem Lett 11(3):228\u2013231. https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00582","journal-title":"ACS Med Chem Lett"},{"key":"9979_CR55","unstructured":"ICH (2024) Final Concept Paper-ICH E14\/S7B IWG Recommended Round 2 Q&As. Endorsed 22 March 2024 https:\/\/database.ich.org\/sites\/default\/files\/E14-S7B_IWG_Final_Concept_Paper_2024_0312_0.pdf:Accessed 4 January 2025"},{"issue":"3","key":"9979_CR56","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1152\/physrev.00017.2023","volume":"104","author":"NA Trayanova","year":"2024","unstructured":"Trayanova NA, Lyon A, Shade J, Heijman J (2024) Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation. Physiol Rev 104(3):1265\u20131333. https:\/\/doi.org\/10.1152\/physrev.00017.2023","journal-title":"Physiol Rev"},{"issue":"2","key":"9979_CR57","doi-asserted-by":"publisher","first-page":"021502","DOI":"10.1063\/1.5132618","volume":"4","author":"M Hwang","year":"2020","unstructured":"Hwang M, Lim CH, Leem CH, Shim EB (2020) In Silico models for evaluating proarrhythmic risk of drugs. APL Bioeng 4(2):021502. https:\/\/doi.org\/10.1063\/1.5132618","journal-title":"APL Bioeng"},{"issue":"8","key":"9979_CR58","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41551-023-01154-7","volume":"8","author":"DM Stresser","year":"2024","unstructured":"Stresser DM, Kopec AK, Hewitt P, Hardwick RN, Van Vleet TR, Mahalingaiah PKS, O\u2019Connell D, Jenkins GJ, David R, Graham J, Lee D, Ekert J, Fullerton A, Villenave R, Bajaj P, Gosset JR, Ralston SL, Guha M, Amador-Arjona A, Khan K, Agarwal S, Hasselgren C, Wang X, Adams K, Kaushik G, Raczynski A, Homan KA (2024) Towards in vitro models for reducing or replacing the use of animals in drug testing. Nat Biomed Eng 8(8):930\u2013935. https:\/\/doi.org\/10.1038\/s41551-023-01154-7","journal-title":"Nat Biomed Eng"},{"key":"9979_CR59","doi-asserted-by":"publisher","first-page":"107860","DOI":"10.1016\/j.cmpb.2023.107860","volume":"242","author":"J Llopis-Lorente","year":"2023","unstructured":"Llopis-Lorente J, Baroudi S, Koloskoff K, Mora MT, Basset M, Romero L, Benito S, Dayan F, Saiz J, Trenor B (2023) Combining Pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity. Comput Methods Programs Biomed 242:107860. https:\/\/doi.org\/10.1016\/j.cmpb.2023.107860","journal-title":"Comput Methods Programs Biomed"},{"key":"9979_CR60","doi-asserted-by":"publisher","first-page":"107498","DOI":"10.1016\/j.vascn.2024.107498","volume":"126","author":"J Aguado-Sierra","year":"2024","unstructured":"Aguado-Sierra J, Dominguez-Gomez P, Amar A, Butakoff C, Leitner M, Schaper S, Kriegl JM, Darpo B, Vazquez M, Rast G (2024) Virtual clinical QT exposure-response studies - A translational computational approach. J Pharmacol Toxicol Methods 126:107498. https:\/\/doi.org\/10.1016\/j.vascn.2024.107498","journal-title":"J Pharmacol Toxicol Methods"},{"key":"9979_CR61","doi-asserted-by":"publisher","first-page":"105368","DOI":"10.1016\/j.yrtph.2023.105368","volume":"139","author":"JP Valentin","year":"2023","unstructured":"Valentin JP, Leishman D (2023) 2000\u20132023 over two decades of ICH S7A: has the time come for a revamp? Regul Toxicol Pharmacol 139:105368. https:\/\/doi.org\/10.1016\/j.yrtph.2023.105368","journal-title":"Regul Toxicol Pharmacol"},{"key":"9979_CR62","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fphar.2010.00137","volume":"1","author":"LS Grilo","year":"2010","unstructured":"Grilo LS, Carrupt PA, Abriel H (2010) Stereoselective Inhibition of the hERG1 potassium channel. Front Pharmacol 1:137. https:\/\/doi.org\/10.3389\/fphar.2010.00137","journal-title":"Front Pharmacol"},{"key":"9979_CR63","doi-asserted-by":"publisher","unstructured":"Yeung C, Baranchuk A (2022) Chap. 1 - Overview of torsades de pointes. In: Tisdale JE (ed) Torsades de Pointes. Academic Press, pp 1\u201326. https:\/\/doi.org\/10.1016\/B978-0-12-821446-6.00013-4","DOI":"10.1016\/B978-0-12-821446-6.00013-4"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-09979-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:43:59Z","timestamp":1752774239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-09979-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9979"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-09979-2","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views and opinions expressed are those of the authors, and do not necessarily represent the views, opinions and\/or policies of their current employers or scientific societies or organizations they are members of. Some authors are employed by pharmaceutical companies and as such might have access to shares and\/or stock options. Furthermore, no de novo generated data was used for the research described in this review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}